drugset / Trial / NCT07093268

Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis

NCT07093268

Phase 1 Not yet recruiting 10 enrolled Brain Trust Bio
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.

Timeline

Start
2025-08-15
Primary completion
2026-06-15
Completion
2027-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule 0.2 mg Intrathecal